Laddar...
SUN-098 Low-Dose Infigratinib Treatment Does Not Lead to Changes in Phosphorous Preclinically in Mice
BACKGROUND: Infigratinib (BGJ398) is a potent and selective FGFR1-3 inhibitor under evaluation for the treatment of achondroplasia, the most common form of disproportionate short stature. Low doses of infigratinib were shown to be effective in improving skeletal abnormalities in a mouse model of ach...
Sparad:
| I publikationen: | J Endocr Soc |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Oxford University Press
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208254/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.552 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|